Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Clinical Study Used to Estimate Central Venous Pressure Non-invasively Using Occlusion Pressure (CV-PRO)

6. Mai 2026 aktualisiert von: Danielle Gottlieb Sen, Le Bonheur Children's Hospital

Non-Invasive Central Venous Pressure Estimation Using Occlusion Pressure: A Novel Approach for Accurate Hemodynamic Monitoring

The purpose of this study is to collect different measurements using a method called peripheral venous pressure (PVP). PVP checks the pressure in the veins in the arms or legs. It can give doctors a good idea of how well the heart is working, similar to another method called central venous pressure (CVP), which doctors use in hospitals. In this study, the research team will measure PVP in people aged 0-17. The researcher hopes that this data will help doctors understand how PVP measurements relate to health outcomes, which could lead to better ways to diagnose and treat patients in the future.

The peripheral venous pressure (PVP) device will be used to non-invasively measure the pressure required to stop blood flow in the forearm, which will indirectly measure the PVP in the forearm. This device is composed of a pressure sensor and a Doppler flow detector that will be connected to a research laptop for data collection. This device will be placed on the forearm.

If you agree to be in this study, the study team will monitor the venous flow rate (the amount of blood moving through the veins over a certain period of time) using a Doppler Flow Detector while applying pressure to the vein with a pressure sensor. This will take place on the forearm.

The internal jugular vein will be identified and recorded using ultrasound imaging and Doppler sensor.

The forearm vein will be identified and marked using ultrasound imaging. Pressure will be applied for 15 seconds, and then stopped and repeated 4 times, making five sets of measurements.

The procedure may be repeated in 2-3 additional sessions during the hospital stay, if necessary.

Your participation in this study will last approximately 30 minutes.

This procedure is for research only and will not affect your regular care. This will occur during your child's stay in the PCICU/PICU. No additional study visits will be required.

The following procedures are being performed for research purposes only:

Copying information such as your medical history from your medical record; Obtaining non-invasive peripheral venous pressure measurements.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

Pediatric congestive heart failure (CHF) is a complex, often end-stage condition affecting around 35,000 children annually in the U.S., with 14,000 hospitalizations and a 6.3% in-hospital mortality rate. CHF occurs when the heart can't meet circulatory demands, leading to increased central venous pressure (CVP), which is currently measured invasively.

In outpatient pediatric care, CHF monitoring relies on subjective symptom reporting and potentially inaccurate weight measurements resulting in a 50% misdiagnosis rate. Recent studies indicate a strong correlation between peripheral venous pressure (PVP) and CVP, suggesting that noninvasive PVP measurements, obtained through occlusion pressure, could accurately estimate CVP.

To test this, the researcher developed a proof-of-concept study using ultrasound, Doppler transducers, and pressure sensors to measure occlusion pressure in veins. This data will be calibrated against direct CVP measurements from central lines using linear regression. The goal is to enhance outpatient monitoring for pediatric CHF, improving diagnostic accuracy by integrating inpatient methods into outpatient settings.

This study will push forward the development of an innovation in pediatric outpatient monitoring, aiming to bring the accuracy and precision of inpatient monitoring into the outpatient settings.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

30

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind

Akzeptiert gesunde Freiwillige

N/A

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Pediatric patients admitted to the Pediatric Intensive Care Unit (PICU) or the Pediatric Cardiac Intensive Care Unit (PCICU) at Le Bonheur Children's Hospital.

Beschreibung

Inclusion Criteria:

  • Admitted to PICU or PCICU
  • Provided written informed consent
  • Continuous Central venous pressure monitoring transduced from a standard central venous catheter (not PICC line)

Exclusion Criteria:

  • Glenn and Fontan Patients
  • Heterotaxy Syndrome Patients
  • Inability to consent by guardian/caretaker

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Pediatric Participants Admitted to the ICU with a Central Venous Catheter
All participants in the study admitted to a pediatric ICU with a central venous catheter in place.
Variable CVP Subset
A subset of approximately 5 participants that have varying ranges of central venous pressure throughout their hospitalization.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean absolute error (MAE) between non-invasive estimated central venous pressure (Doppler-coupled occlusion-pressure device) and invasive central venous pressure (central venous catheter)
Zeitfenster: At time of single study session, up to 60 minutes
Unit of Measure: mmHg For each participant, the non-invasive estimated CVP value derived from the Doppler-coupled occlusion-pressure measurement (5 technical replicates per session) will be compared to the simultaneous invasive CVP value obtained from the central venous catheter (standard of care). The primary reportable outcome is the MAE across participants, defined as the mean of the absolute difference between paired estimated and measured CVP values, expressed in mmHg. The pre-specified target is MAE ≤ 2 mmHg, consistent with the sample-size justification (n=25 to achieve 80% power assuming an acceptable margin of error of 2 mmHg, a Type I error rate of 5%, and an expected standard deviation of 4 mmHg from prior literature). Intermediate algorithm inputs including vein-occlusion pressure, initial vein diameter, Doppler-isolated venous waveform characteristics, internal jugular vein Doppler recording, and intrapatient and interpatient variability of device output.
At time of single study session, up to 60 minutes

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Correlation between non-invasive estimated central venous pressure and invasive central venous pressure, adjusted for concurrent physiologic context variables abstracted from the electronic medical record
Zeitfenster: At time of single study session, up to 60 minutes
Unit of Measure: Pearson correlation coefficient (r), unitless, range -1.00 to +1.00 Strength of the linear association between the non-invasive estimated CVP (Doppler-coupled occlusion-pressure device) and simultaneous invasive CVP (central venous catheter). The regression model will adjust for concurrent physiologic context variables abstracted from the EMR at the single study session - collected as standard of care, with no extra research procedures: heart rate, cardiac rhythm, respiratory rate, non-invasive and arterial-line blood pressure (systolic, diastolic, MAP), SpO2, ETCO2, awRR, mixed venous oxygen saturation, stroke volume, cardiac output, and intracardiac chamber pressures. Only readily available EMR parameters will be recorded; no procedures will be added to obtain missing data.
At time of single study session, up to 60 minutes

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Le Bonheur Children's Hospital

Mitarbeiter

The Brett Boyer Foundation

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

1. Juli 2027

Studienabschluss (Geschätzt)

1. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

1. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. Mai 2026

Zuerst gepostet (Tatsächlich)

13. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 25-10829-FB: CV-PRO

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Kongestive Herzinsuffizienz

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Kuwait

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren